resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA ...

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Biotech Analyst Kim holds a conference call with Dr. Sullivan, Chief Product Strategy Officer, to discuss INSM‘s TPIP (Treprostinil Palmitil ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin drug treprostinil. The patch, applied once daily, delivers an inactive prodrug (TRX-248 ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial ...

PRINT enabled the creation of Liquidia's lead candidate, YUTREPIA (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.

Commercially available solutions of treprostinil sodium a, b were diluted in sterile water for injection, c 0.9% sodium chloride injection, d and 5% dextrose injection. e The concentrations tested ...

Revenue decreased by $3.5 million in 2024 compared to 2023, attributed to lower sales quantities linked to limitations on the availability of necessary pumps for administering Treprostinil Injection.